
I have written about Johnson & Johnson (JNJ) several times in the past, but since the last article was around 8 months ago, I think an update is in order. That article was in response to an article that saw Medtronic (MDT) as a good replacement for JNJ. I saw JNJ as the superior investment. At the time, while I saw JNJ as the superior investment, I did not recommend buying it as it was trading nearly $20 above the value I placed on its dividend stream.
In an even earlier article, I talked about the idea that an investor could be paid by agreeing to buy 100 (or multiples thereof) shares of JNJ for $120 on or before July 21, 2017. I figured an investor could collect $160 for every put contract they were willing to write. So how did that work out? Did the investor get the shares or did they just have to settle for collecting the premium?
READ FULL ARTICLE HERE

